Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Johnson & Johnson's teclistamab wins CHMP backing for expanded use in earlier multiple myeloma treatment
Bispecific antibody, multiple myeloma, oncology, regulatory - Read more

AbbVie's Rinvoq (upadacitinib) wins European Commission approval for pediatric polyarticular juvenile idiopathic arthritis via Ph1 data
Small molecule, autoimmune, JAK inhibitor, juvenile idiopathic arthritis, pediatric patients - Read more

Menarini Group, NewAmsterdam Pharma receive European Commission approval for Ubeslo and Evlarco (obicetrapib), targeting hypercholesterolaemia
Small molecule, cardiovascular, CETP inhibitor, hypercholesterolemia, LDL-C reduction, combination therapy - Read more

Boehringer Ingelheim, Envisagenics sign $1B multi-year oncology collaboration leveraging AI RNA splicing platform SpliceCore
Research collaboration, oncology, AI/ML, drug discovery, antibody, milestone payments - Read more

AbbVie, Iambic partner on AI drug discovery across immunology, neuroscience and oncology with milestones and royalties
Research collaboration, AI/ML, small molecule, oncology, neuroscience, milestone payments - Read more

Novartis licenses preclinical radioligand therapy from BoomRay Pharmaceuticals for up to $900M
Licensing deal, oncology, radioligand therapy, milestone payments, royalties - Read more

Insilico Medicine partners with AI foundation model lab on generative biology models worth tens of millions
Co-development, AI/ML, drug discovery, generative biology, revenue-sharing - Read more

ExploRNA Therapeutics, Łukasiewicz - IChP partner on GMP manufacturing of next-generation mRNA cap analogs
Manufacturing agreement, mRNA, vaccine, drug discovery, GMP manufacturing - Read more

DRI Healthcare acquires tavapadon royalty rights from Bain Capital, NovaQuest for $316M
Royalties, neurological, small molecule, milestone payments - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

J&J's Caplyta (lumateperone) meets Ph3 primary endpoint in bipolar I disorder-associated manic episodes
Small molecule, neurological, atypical antipsychotic, bipolar disorder, lumateperone - Read more

Otsuka, Ionis Pharmaceuticals' (ulefnersen) hits Ph3 primary endpoint for FUS-ALS, advancing toward FDA discussions
Antisense oligonucleotide, neurological, ALS, FUS gene mutation, RNA-targeted therapy - Read more

Vertex's (inaxaplin) Ph2b trial shows positive results in APOL1-mediated kidney disease patients
Small molecule, kidney disease, APOL1-mediated kidney disease, proteinuria, inaxaplin - Read more

Amgen's (dazodalibep) hits Ph3 primary endpoint, easing Sjögren's disease severity via CD40 ligand targeting
Protein therapy, autoimmune, fusion protein, Sjögren's disease, CD40 ligand, CD40L mechanism - Read more

Celldex's barzolvolimab achieves Ph3 wins in chronic spontaneous urticaria, targeting KIT receptor
Antibody, autoimmune, monoclonal antibody, chronic spontaneous urticaria, KIT receptor, mast cell - Read more

Roche's (enicepatide) cuts blood sugar, body weight in Ph2 trial for type 2 diabetes with obesity
Protein therapy, metabolic, GLP-1/GIP dual receptor agonist, type 2 diabetes, weight loss, enicepatide - Read more

Opterion Health's OPT101 shows positive Ph1 results in chronic kidney disease, advancing to Ph2a peritoneal dialysis study
Protein therapy, metabolic, peritoneal dialysis, chronic kidney disease, non-glucose-based solution - Read more

Viking Therapeutics' (VK2735) Ph2 maintenance data show up to 97% weight loss retention in adults with obesity
Small molecule, metabolic, GLP-1/GIP receptor agonist, obesity, incretin therapy, subcutaneous injection - Read more

Iambic Therapeutics files for IPO, advancing AI-driven HER2 inhibitor IAM1363 for solid tumors
AI-driven, small molecule, oncology, clinical-stage, HER2, platform technology - Read more

Axio BioPharma raises $2.4M pre-seed to connect pharma manufacturing data across companies
Manufacturing, software platform, data analytics, biologics, CDMO - Read more

ADARx Pharmaceuticals plans $350M IPO plus $80.1M placement, advancing siRNA precision medicines
siRNA, cardiovascular, rare disease, neurological, clinical-stage, platform technology - Read more

AstronauTx awarded research funding from Michael J. Fox Foundation and Parkinson's UK, exploring sleep-based Parkinson's treatments
Neurological, small molecule, Parkinson's disease, Alzheimer disease, sleep architecture, preclinical - Read more

Biolevate raises €30M ($34.4M) Series A, AI agentic platform for life sciences operations
AI/ML platform, software platform, regulatory, drug discovery, clinical trials - Read more

Sleuth forecasts Western licensing deals for Chinese radioligand therapies to surge in 2027
Radioligand therapy, oncology, strategic, supply chain - Read more

Lexeo Therapeutics acquires Mantle Therapeutics for up to $21.3M to expand Friedreich's ataxia pipeline
Small molecule, rare disease, strategic, major transaction - Read more

Novo plans 10-fold expansion of oral Wegovy manufacturing capacity by 2030 to serve more patients
Small molecule, metabolic disease, operational, manufacturing capacity - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Trump proposes splitting childhood vaccines into smaller doses, claiming unproven autism reduction benefits
Vaccine, pediatric, regulatory, operational - Read more

Pfizer, Lilly MFN drug pricing deals reveal GLP-1 exemptions and revenue-sharing clauses, raising patient savings doubts
Small molecule, metabolic disease, pricing policy, regulatory - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here